AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca PLC's (LON:AZN) trial results on the COVID-19 vaccine developed with Oxford University have been questioned by a US agency. The National Institute of Allergy and Infectious Diseases (NIAID) said on Tuesday that the pharma company should review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.

US agency asks AstraZeneca to review COVID-19 vaccine trial results

Drug firm may have provided incomplete view of efficacy data from US trial, says safety monitor

US agency questions AstraZeneca's Covid vaccine trial data

The U.S. government agency has urged AstraZeneca to review the efficacy data and ensure the most accurate, up-to-date data is made public.

AstraZeneca May Have Included “Outdated Information” In U.S. Trial Results, NIAID Says

The statement comes just one day after the findings of a large U.S. trial had shown the Oxford-AstraZeneca vaccine is safe and highly effective.

U.S. health agency casts doubt over AstraZeneca's Covid vaccine trial data

Results of a U.S. trial of AstraZeneca's COVID-19 vaccine may have included "outdated information," providing an "incomplete view of the efficacy data," said Federal health officials said early Tuesday.

U.S. health officials say AstraZeneca may have relied on ‘outdated information' over COVID-19 trial

AstraZeneca Plc (NASDAQ: AZN) says that it expects the European Medical Agency's (EMA) approval for a factory in the Netherlands later this month or early April. What Happened: According to Reuters, the facility has been at the center of a row between Britain and the European Union over COVID-19 vaccine supplies.

AstraZeneca Bullish On Receiving EU Approval For Dutch Factory By Early April: Reuters

There were no similar surge in vaccine fears for shots by Pfizer and Moderna.

European Trust In AstraZeneca's Covid-19 Shot Plummets Amid Politicized Blood Clot Scare

Jefferies healthcare analyst Peter Welford said the analysis of the AstraZeneca shot, published Monday, was better than expected.

Analysts cheer ‘surprisingly positive' AstraZeneca U.S. trial data

The COVID-19 vaccine of the U.K.-Swedish pharmaceuticals group AstraZeneca has shown robust results in its U.S. trial, the company said on Monday.

AstraZeneca's new COVID-19 vaccine trial data will give the shot a U.S. boost

AstraZeneca stock moved higher on Monday after its vaccine was shown to be 79% effective at stopping symptomatic Covid-19 in U.S. clinical trials.

AstraZeneca Vaccine Found to Be Safe and 79% Effective in U.S. Trial

The latest Phase III trial encompassed 32,000 participants, 21,583 of those receiving at least one dose of the AstraZeneca vaccine. The beleaguered AstraZeneca COVID-19 vaccine got a big shot in the arm, so to speak, today with results of the latest clinical trial which showed the vaccine is 79% effective against the virus.

AstraZeneca's COVID-19 vaccine has 79% efficacy in new U.S.-based trial

AstraZeneca Plc's (NASDAQ: AZN) says interim data from U.S. clinical trials in over 32,000 people shows its COVID-19 shot is 79% effective and safe. What Happened: The vaccine was also shown to be 100% effective at preventing severe disease, death, and hospitalization.

AstraZeneca's COVID-19 Shot Shows 79% Efficacy In US Trials

AstraZeneca says the large scale trials showed no safety concerns with regard to blood clots.

AstraZeneca Vaccine 100% Effective In Preventing Severe Disease And Hospitalizations, U.S. Trials Show

AstraZeneca PLC (LON:AZN) said the COVID-19 vaccine developed with Oxford University showed 100% efficacy against severe or critical disease and hospitalisation in late-stage trials. The FTSE 100 pharma company said the jab was well tolerated, and the independent data safety monitoring board (DSMB) identified no safety concerns related to the vaccine.

AstraZeneca says COVID-19 vaccine shows 100% efficacy against severe disease, hospitalisation with no safety concerns

The COVID-19 vaccine co-developed by AstraZeneca and University of Oxford was 79% effective at protecting against coronavirus in the vaccine's largest trial yet, the drugmaker said on Monday. The drugmaker can now submit the data from the trial to be scrutinized by the US regulator, the Food and Drug Administration.

AstraZeneca's COVID-19 shot was 79% effective in large trial, paving the way for approval in the US despite troubles in Europe

The coronavirus vaccine developed by AstraZeneca and the University of Oxford has been found to be 79% effective in a large U.S. trial.

AstraZeneca coronavirus vaccine found to be 79% effective in U.S. trial

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In AstraZeneca To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - March 21, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN) and reminds investors of the March 29, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.If you suffered losses exceeding $50,000 investing in AstraZeneca stock or options between May 21,...

Astrazeneca Update

BioNTech SE

Johnson & Johnson

Moderna

Novavax

Pfizer

Some stocks could be big winners and losers depending on what the answer to this question is.

The Multibillion-Dollar Question: How Long Do COVID Vaccines Last?

NEW YORK, March 20, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline. SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

AZN INVESTOR ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important March 29 Deadline in Securities Class Action - AZN

Boston, Massachusetts--(Newsfile Corp. - March 20, 2021) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of AstraZeneca PLC (NASDAQ: AZN). The case is currently in the lead plaintiff stage. Investors who purchased AZN stock or other securities between May 21, 2020 and November 20, 2020 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/AstraZeneca to submit their information. Investors may also...

AstraZeneca Investor Alert: Shareholder Lawsuit Filed

Isolating the cause has allowed scientists to develop a treatment for the blot clots once diagnosed.

European Scientists Say They Know Why AstraZeneca's Vaccine Is Causing Rare Blood Clots

Finland investigates possible blood clots as others in Europe resume AstraZeneca Covid-19 shots and France is forced into new lockdowns.

Nordic Countries Outliers as Europe Resumes Use of AstraZeneca Shot

The panel said AstraZeneca's coronavirus vaccine had “tremendous potential” to prevent cases and deaths, reaffirming support for the shot after concerns over blood clots prompted some European nations to temporarily suspend use of it.

WHO Stands Behind AstraZeneca Coronavirus Vaccine After Blood Clot Concerns

France has changed its guidance on the shot three, initially restricting it to those under 65 years of age.

Europe's Flip-Flopping Over AstraZeneca's Covid-19 Vaccine Continues: France Ignores Regulator And Limits Shot To Over-55s

The French government announced on Thursday that the whole greater Paris region will be placed under lockdown, forcing President Emmanuel Macron to backtrack on his insistence that such strict measures could be avoided.

News for AstraZeneca Stock (AZN)